Navigation Links
Bioniche Phase III Clinical Trial with Urocidin(TM) Given Continued Green Light by DMC
Date:8/24/2009

muscle-invasive bladder cancer.

In September, 2007, the Company announced that an agreement had been reached with the FDA under the Special Protocol Assessment (SPA) procedure on the design of the trial, including its endpoints, data analysis and conduct. It provides assurance that, if the trial endpoints are met, they will serve as the basis for product approval under a Biologics Licensing Application (BLA). An SPA gives a clear pathway to registration of Urocidin when the trial endpoints are achieved. This indication for MCC received Fast Track designation by the FDA last year.

About Bladder Cancer

In North America, bladder cancer is the fourth most common cancer in men and in the top ten for women. In the United States, approximately 70,000 patients are newly diagnosed with bladder cancer each year. In addition, the cancers of many previously-diagnosed patients remain unresolved, sometimes leading to cystectomy (bladder removal) or death. Approximately 70 percent of bladder cancer patients have the non-muscle-invasive form of bladder cancer at diagnosis and, on appropriate regulatory approvals, might be eligible for multiple treatments with Urocidin.

Non-muscle-invasive bladder cancer is a form of bladder cancer localized in the surface layers of the bladder that has not yet spread into the deeper muscle layer. This form of bladder cancer is treated predominantly by urologists using surgical resection and intravesical infusion therapy. Urocidin is an intravesical infusion therapy, administered via trans-urethral catheter into the bladder.

About Urocidin(TM)

Urocidin is a formulation of MCC, a sterile mycobacterial cell wall-DNA complex composition that has a dual mode of action: immune stimulation and direct anticancer activity. Urocidin is formulated for the treatment of bladder cancer, where it is administered by trans-urethral catheter directly into the bladder, coming into con
'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Bioniche Repays Revolving Credit Facility
2. Bioniche Provides a Corporate Update
3. Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
4. Bioniche Represented at House of Commons Sub-Committee on Food Safety
5. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
6. Bioniche Reports Fiscal 2009 Third Quarter
7. Bioniche Provides a Corporate Update
8. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
9. Bioniche Revolving Credit Facility Maturity Date Amended
10. Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology
11. Bioniche Warrants Expiration Date to be Extended
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... activity monitors hold great promise in helping people ... increasingly sophisticated devices help the wearers improve their ... responses. This information is organized into companion computer ... large and quickly growing market for these devices, ... at Galveston analyzed 13 of these activity monitors, ...
(Date:9/16/2014)... magnesium sulfate is routinely given to pregnant women at ... won,t provide any long-term benefits for infants. ... pregnant women, researchers in Australia found it had no ... those children when they were assessed at between 6 ... negate the fact that the drug is helpful in ...
(Date:9/16/2014)... therapy as part of breast conservation is the ... positive (HR+) invasive breast cancer. A new study ... shows that combination may not be necessary for ... The results, which Fox Chase researchers presented at ... Meeting on Sunday, September 14, suggest that low-risk ...
(Date:9/16/2014)... DC (PRWEB) September 16, 2014 Programs ... potentially yield hundreds of billions of dollars in savings ... report by the Commonwealth Fund. To help spur these ... seeking up to 10 collaborative groups from across the ... 1.0 ( http://bit.ly/1wo4gsa ) - a handbook designed to ...
(Date:9/16/2014)... 16, 2014 Who:, The Pulmonary Hypertension ... Campus and Children’s Hospital Colorado are hosting ... country’s leading pulmonary hypertension association that works to find ways ... of the lungs that affects the functioning of the heart ... survivability is only 2.8 years. , What:, Colorado PH ...
Breaking Medicine News(10 mins):Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3Health News:Researchers Don't See Long-Term Benefits From Drug for Preemies 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:NQF Seeks Field Testing Groups for Population Health Guide 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 3Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2
... Push for More Charity Care After County,Assessor Reports ... CHICAGO, Nov. 8 Joined by union ... on Thursday,said the State and County should require ... justify their tax exemptions by providing more,charity care ...
... Adaptis, a business integration,provider focused exclusively on ... Inc., has purchased HealthASPex (HAX) through an,asset ... and PPO routing,services to Third Party Administrators ... http://www.newscom.com/cgi-bin/prnh/20050113/SFTH042LOGO ) "Tela,s streamlined front-end ...
... and e-Health, a publication available in print and on-line by ... expand its content and frequency beginning in 2008; a new ... issue. , A new format ... enables more news, roundtable discussions, case studies, interviews with leaders ...
... topic of cancer prevention is covered widely in the ... information and complex scientific research that is not easily ... for Cancer Research (AACR) and Susan G. Komen for ... scientific research community and journalists who cover cancer science ...
... Make Breast Cancer ... Nov. 8 Washington State has the highest rate,of breast ... of Susan G. Komen for the Cure will host a ... policymakers to increase the budget for,screening programs for low-income women ...
... Develop a New Thrombectomy ... to Remove Clots in Blood Vessels, ST. PAUL, Minn., ... Dakota state lawmakers, with the support of Governor John Hoeven,and ... for Enova Medical Technologies, the University of North Dakota (UND),and ...
Cached Medicine News:Health News:Charity Care Hospitals Told to Put Up or Pay Up in Wake of New Report 2Health News:Charity Care Hospitals Told to Put Up or Pay Up in Wake of New Report 3Health News:Tela Sourcing, Inc., an Adaptis Company, Acquires HealthASPex Business 2Health News:Telemedicine publication expands coverage 2Health News:Puget Sound Komen for the Cure, Former First Lady Mona Locke, Washington Health Leaders and Breast Cancer Survivors Call for Action to Reduce State's High Breast Cancer Incidence 2Health News:North Dakota Grants Enova Medical Technologies a $2.5 Million Centers of Excellence Grant 2
(Date:9/16/2014)... 2014 Research and Markets ... Laparoscopy Devices Industry Report 2014" report to ... Devices Industry Report 2014 is a professional and ... global laparoscopic devices. The report provides ... classifications, applications and industry chain structure. The laparoscopic ...
(Date:9/16/2014)... 2014   Vestagen Technical Textiles, Inc. today ... hospitals. The myComfort™ line of patient apparel is protected ... is fluid repellant, breathable and in studies done in ... bacteria on the fabric i . "It,s ... chain of transmission. We want myComfort to be a ...
(Date:9/16/2014)... CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... and restatement of its outstanding Series C-2, C-3, ... as well as the warrants issued in its ... remove anti-dilution, price reset and certain change of ...
Breaking Medicine Technology:Global Laparoscopy Devices Industry Report 2014 2New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3
... Multichannel, with it's streamlined design, ... routine laboratory tasks. The multichannel ... Soft-touch tip ejection, Super blow-out ... models), Entire pipette autoclavable, streamlined ...
... wide variety of applications. • Whole pipette is ... freely rotated against the handle to work in ... angle towards the microtiter plate. • The special ... common pipette tips, and provides a firm, parallel ...
... with 96-well plates in mind, Pipetman ... molecular biology applications: PCR* sequencing, immunology ... etc. Used with Diamond Tips from ... product will maximize performance and assure ...
... Multichannel, with it's streamlined design, ... routine laboratory tasks. The multichannel ... Soft-touch tip ejection, Super blow-out ... models), Entire pipette autoclavable, streamlined ...
Medicine Products: